When researchers screened a library of more than 200 drugs and related compounds for activity against
embryonal subtype tumor cells from three patients, the most promising results involved drugs that increased oxidative stress in tumor cells.
About 60 percent of rhabdomyosarcoma patients have tumors of
the embryonal subtype, and about 25 percent have the alveolar subtype.
Not exact matches
Embryonal rhabdomyosarcoma included far more genomic alterations than alveolar
subtype tumors.